The mature c-terminal domain of filamentous hemagglutinin is sufficient to provide protection against Bordetella pertussisin the murine nasal cavity

M. Barbier,F. Damron,Kelly L. Weaver,Annalisa B. Huckaby,William T. Witt,G. Pyles,Margalida Mateu-Borrás
DOI: https://doi.org/10.4049/jimmunol.210.supp.253.12
2023-05-01
Abstract:Bordetella pertussis is the causative agent of whooping cough. The transition from whole cell (wP) to acellular pertussis vaccines (aPs) triggered an increase in pertussis incidence despite wide-spread vaccine coverage. aPs contain protein antigens purified from B. pertussis: pertactin, fimbriae, filamentous hemagglutinin (FHA), and pertussis toxin (PT). Antibodies are critical for protection against B. pertussis, and have been demonstrated to trigger opsonization, block bacterial adhesion, and neutralize disease symptoms. Following aP-vaccination, however, antibodies target a diminished number of functional B cell epitopes as the antigens are chemically denatured during aP manufacturing. The effects of denaturation on PT are well documented, but this has not been studied for other vaccine antigens, such as FHA. Additionally, FHA is a large antigen, and most of the protein does not play a role in bacterial adhesion. To direct antibody responses toward non-denatured, functionally relevant portions of FHA we aimed to test the Mature C-terminal Domain (MCD) of FHA as vaccine antigen. Protection provided by MCD was compared to several vaccine preparations, including aP and native FHA. We observed that aP and wP vaccines lead to the induction of antibodies that recognize FHA, MCD and B. pertussis. Using a CD-1 murine model of vaccination and challenge we demonstrated that MCD is immunogenic and sufficient to decrease bacterial burden in the murine airway, providing ~85% reduction in B. pertussis present in the nasal cavity. Overall, our data supports the use of MCD as a vaccine antigen for protection against B. pertussis. Ongoing studies focus on the selection of the adjuvants and route of administration to optimize vaccine efficacy. Mariette Barbier is funded by NIH grant 5R01AI141671-04. Fredrick Damron is funded by NIH grant 5R01AI137155-04. The Vaccine Development Center Research Challenge Grant (no. HEPC.dsr.18.6) from the Division of Science and Research, WV Higher Education Policy Commission also contributed support.
Biology,Medicine
What problem does this paper attempt to address?